Resource Capital Corp. (NYSE:RSO) shares advanced 0.82% in last trading session and ended the day at $11.03. RSO Gross Margin is 52.90% and its has a return on assets of -0.50%. Resource Capital Corp. (NYSE:RSO) quarterly performance is -14.56%.
Resource Capital Corp. (NYSE: RSO) announced that it will pay a cash dividend on its 8.50% Series A Cumulative Redeemable Preferred Stock for the period from January 31, 2016 through and including April 30, 2016 in the amount of $0.53125 per share. The dividend will be payable on May 2, 2016 to holders of record on April 1, 2016.
Pfizer Inc. (NYSE:PFE) ended the last trading day at $32.93. Company weekly volatility is calculated as 3.12% and price to cash ratio as 8.64. Pfizer Inc. (NYSE:PFE) showed a weekly performance of 9.51%.
Pfizer Inc. (NYSE: PFE) announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies.
On 06 April, CPI Card Group, Inc. (NASDAQ:PMTS) shares advanced 4.88% and was closed at $8.39. CPI Card Group, Inc. (NASDAQ:PMTS) year to date (YTD) performance is -21.29%.
CPI Card Group (NASDAQ:PMTS), announced it will host a live conference call on Wednesday, May 11, 2016 at 5:00 p.m. Eastern Time (ET) to discuss its first quarter 2016 financial results. Participating on the call will be CPI Card Group President and CEO Steve Montross and CFO David Brush.
Energy Transfer Equity, L.P. (NYSE:ETE) shares advanced 7.60% in last trading session and ended the day at $6.94. ETE Gross Margin is 19.30% and its has a return on assets of 2.10%. Energy Transfer Equity, L.P. (NYSE:ETE) quarterly performance is -48.49%.
On March 31, 2016, Energy Transfer Equity, L.P. (NYSE:ETE) and Sunoco LP (“SUN”) closed the previously announced sale by SUN to ETE of 2,236,158 common units representing limited partner interests in SUN (the “SUN Common Units”) in a private transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933 (the “PIPE Transaction”). In connection with the PIPE Transaction, ETE entered into a registration rights agreement with SUN (the “Registration Rights Agreement”), pursuant to which SUN is required to file a shelf registration statement to register the SUN Common Units upon the request of the holders of a majority of the then-outstanding SUN Common Units.
Flexion Therapeutics, Inc. (NASDAQ:FLXN) caters to the Healthcare space. Its weekly performance is 36.67%. On the last day of trading company shares ended up at $12.30.
On April 4, 2016, Flexion Therapeutics, Inc. (NASDAQ:FLXN) reported additional results from Phase 2b and Phase 3 clinical trials for its lead drug candidate, Zilretta (also known as FX006). The Phase 3 trial was a randomized, double-blind, placebo-controlled, active-comparator trial that enrolled 486 patients at approximately 40 centers worldwide. Patients were randomized to one of three treatment groups (1:1:1) and received either a single intra-articular injection of 40 mg of Zilretta, normal saline (placebo) or 40 mg of immediate-release triamcinolone acetonide (“TCA”). Each patient was evaluated for efficacy and safety during seven outpatient visits over 24 weeks after receiving an injection. The primary objective of the study was to assess the magnitude of pain relief of Zilretta at 12 weeks against placebo as measured by the weekly mean of the average daily pain (“ADP”) score.
Leave a Reply